Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TV
Tvardi Therapeutics, Inc. Common Stock
TVRD
Mkt Cap
$13.5M
Volume
91.03K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TV
TVRD
TV
Tvardi Therapeutics, Inc. Common Stock
TVRD
News
·
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
Mkt Cap
$14.3M
Volume
91.03K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
Tvardi Therapeutics, a clinical-stage biopharmaceutical company developing STAT3-targeting therapies, announced it will present at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The company is advancing TTI-109 for gastrointestinal diseases and TTI-101 in a Phase 1b/2 trial for hepatocellular carcinoma, with preclinical data supporting potential in ulcerative colitis treatment.
GlobeNewswire Inc. · Oct 14, 2026
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight
The idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designations, positive clinical trial data, and FDA clinical hold lifts for several promising candidates in 2025-2026.
GlobeNewswire Inc. · Feb 9, 2026
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Tvardi Therapeutics (NASDAQ: TVRD) experienced an 80% stock decline on October 13, 2025, after disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis. The study failed to meet its primary goals regarding safety and lung function outcomes. A securities law firm is now investigating potential claims on behalf of affected investors.
GlobeNewswire Inc. · Dec 24, 2025
SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Tvardi Therapeutics' stock plummeted over 80% on October 13, 2025, following disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis. The study failed to meet its primary goals regarding safety and efficacy outcomes. Securities law firm Faruqi & Faruqi is investigating potential claims on behalf of affected investors.
GlobeNewswire Inc. · Dec 20, 2025
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Tvardi Therapeutics experienced significant stock decline after disappointing Phase 2 clinical trial results for TTI-101 in idiopathic pulmonary fibrosis, with preliminary data showing the study did not meet its goals.
GlobeNewswire Inc. · Nov 29, 2025
TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Tvardi Therapeutics experienced an 80% stock drop after disappointing Phase 2 clinical trial results for TTI-101 in idiopathic pulmonary fibrosis, with preliminary data showing the study did not meet its goals.
GlobeNewswire Inc. · Nov 9, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
TV
TVRD
Tvardi Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
TVRD
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any TVRD yet.
Related Tickers
Earnings